Summary of UnitedHealth Group's Q3 2026 Earnings Report

Overview

UnitedHealth Group Inc. (UNH.US), a leading US health insurance provider, reported its third-quarter earnings for 2026, showcasing results that surpassed Wall Street expectations in both revenue and earnings per share (EPS). Following the announcement, shares rose nearly 3% due to improved operating profitability and a favorable medical care ratio.

Key Financial Metrics

• Group Revenue: $112.69 billion (expected: $111.03 billion)
• Adjusted EPS: $4.69 (consensus estimate: $4.12)
• Reported EPS: $4.56 (up from $2.59 a year ago, representing a 76% year-over-year growth)
• UnitedHealthcare Revenue: $86.33 billion (forecast: $84.87 billion)
• Optum Revenue: $66.88 billion (slightly above consensus of $66.48 billion)
• Total Enrollment: 48.3 million (below expectations of 48.62 million)
• Medical Care Ratio (MCR): 88.4% (expected: 89.9%)
• Operating Margin: 5.8% (up from 3.8% year-over-year)
• Operating Cost Ratio: 12.8% (slightly above expectations of 12.6%)

Guidance and Future Outlook

UnitedHealth raised its full-year 2026 adjusted EPS guidance to at least $20.50, up from the previous range of $19.50–$20.00. The reported EPS guidance was also increased to at least $19.50, compared to the earlier range of $18.45–$18.95. This upward revision indicates management's confidence in the company's performance as the year progresses.

Market Reaction and Stock Performance

The stock has faced challenges and is currently trading approximately 40% below its all-time highs. However, the positive market reaction to the earnings report suggests a potential breakout above the key 200-session exponential moving average (EMA200), which could pave the way for the stock to reach levels of $400 and $440.

Long-Term Considerations

While UnitedHealth's revenue trajectory remains positive, recent quarters indicate that revenue growth does not always correlate with improved profitability. The company reported a net income of around $5.5 billion in Q2 2026, with a net profit margin of 4.9%. The return on invested capital (ROIC) stands at 14.3%, reflecting meaningful returns on capital deployed. The market is currently pricing in a continued earnings recovery, with a trailing P/E ratio of 24.3 and a forward P/E of 19.2. Future performance will depend on maintaining revenue growth, improving margins, controlling medical costs, and generating higher returns on invested capital.